LNTH - Lantheus Holdings, Inc.
About Lantheus Holdings, Inc. (https://www.lantheus.com)
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Ludger Dinkelborg | Head of Research & Development | 1963 | $13,659,644 USD |
| Brian A. Markison | Strategic Advisor | 1959 | $1,440,685 USD |
| Robert J. Marshall Jr. | Chief Financial Officer & Treasurer | 1967 | $991,665 USD |
| Jean-Claude Provost | Chief Science Officer | 1963 | $894,790 USD |
| Thomas Reiner | Chief Science Officer | – | $894,790 USD |
| Daniel Niedzwiecki | Chief Administrative Officer, General Counsel & Corporate Secretary | 1977 | $763,085 USD |
| Amanda Morgan | Chief Commercial Officer | 1979 | $677,449 USD |
| Mary Anne Heino | Interim CEO & Executive Chairperson | 1960 | $673,968 USD |
| Dorothy Barr | Senior Vice President of Manufacturing & Technical Operations | – | – |
| Kimberly Brown | Chief Accounting Officer | 1991 | – |
| Lee Anne Howe | Chief Information Officer | – | – |
| Mark Richard Kinarney | Vice President of Investor Relations | – | – |
| Neil Holland | Vice President of Business Insights & Operations | – | – |